HeartBeam Buy Rating Reiterated as Clinical and Commercial Momentum Strengthens; $2 Price Target MaintainedTip Ranks·Aug 18 at 04:55 PMBEAT-3.26%
HeartBeam enters ATM equity sales agreement for up to $25 million common stock offeringPUBT·Aug 14 at 09:06 PMBEAT-3.26%
HeartBeam Launches $25 Million At-The-Market Offering With Titan Partners SecuritiesTradingView·Aug 14 at 09:03 PMBEAT-3.26%
HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga_article·Aug 13 at 09:35 PMBEAT-3.26%
HeartBeam Q2 2026 results: Cash-burn outlook improves as net loss holds near $5 millionTradingKey·Aug 13 at 08:20 PMBEAT-3.26%
HeartBeam posts Q2 presentation outlining heart attack detection progress and initial commercial launch tractionPUBT·Aug 13 at 08:15 PMBEAT-3.26%
BEAT: Net loss narrowed, liquidity remains a concern, and strategic focus shifts to licensing and pilot studiesQuartr·Aug 13 at 08:08 PMBEAT-3.26%
BEAT: Net loss and cash outflow declined as clinical and commercial milestones advanced, extending cash runwayQuartr·Aug 13 at 08:08 PMBEAT-3.26%
HeartBeam Q2 FY26 net loss narrows to $5 million; SG&A expenses rise to $2.76 millionPUBT·Aug 13 at 08:01 PMBEAT-3.26%
